| Filed On | Filing |
|---|---|
| 17 Sep 2026 |
Form 4: Denner Alexander J, Director
Received 3,694 shares as a grant or award |
| 22 Jul 2026 |
Form 4: Silber Jeffrey, SVP, CMO, Head-Res&Drug
Received 137,036 shares as a grant or award |
| 09 Jul 2026 |
Form 4: Silver Ronald, PFO & PAO
Sold 127,890 shares ($578K) |
| 17 Jun 2026 |
Form 4: Shepard Jay, Director
Received 63,481 shares as a grant or award |
| 17 Jun 2026 |
Form 4: Kessler Marla L, Director
Received 63,481 shares as a grant or award |
| 17 Jun 2026 |
Form 4: Currie Mark G, Director
Received 63,481 shares as a grant or award |
| 17 Jun 2026 |
Form 4: Duane Jon R, Director
Received 63,481 shares as a grant or award |
| 17 Jun 2026 |
Form 4: Denner Alexander J, Director
Received 4,065 shares as a grant or award · Received 63,481 shares as a grant or award |
| 17 Jun 2026 |
Form 4: McHugh Julie, Director
Received 63,481 shares as a grant or award · Sold 21,571 shares ($80.5K) |
| 17 Jun 2026 |
Form 4: Moukheibir Catherine, Director
Received 63,481 shares as a grant or award |
| 21 May 2026 |
Form 4: Silver Ronald, PFO & PAO
Received 25,000 shares as a grant or award |
| 17 Mar 2026 |
Form 4: Denner Alexander J, Director
Received 4,451 shares as a grant or award · Sold 6,730,800 shares ($20.5M) |
| 12 Mar 2026 |
Form 4: John Minardo, Chief Legal Officer
Received 136,612 shares as a grant or award |
| 12 Mar 2026 |
Form 4: Martini Gregory S., Chief Financial Officer
Received 136,612 shares as a grant or award |
| 12 Mar 2026 |
Form 4: Gaskins Tammi L, Chief Commercial Officer
Received 136,612 shares as a grant or award |
| 12 Mar 2026 |
Form 4: Shetzline Michael, SVP, CMO, Head-Res&Drug
Received 136,612 shares as a grant or award |
| 12 Mar 2026 |
Form 4: Silver Ronald, Principal Accounting Officer
Received 163,934 shares as a grant or award |
| 12 Mar 2026 |
Form 4: Mccourt Thomas A, Director
Received 409,836 shares as a grant or award |
| 25 Feb 2026 |
Form 4: John Minardo, Chief Legal Officer
Sold 17,439 shares ($66.4K) · Sold 19,053 shares ($69.7K) |
| 25 Feb 2026 |
Form 4: Shetzline Michael, SVP, CMO, Head-Res&Drug
Sold 15,570 shares ($59.3K) · Acquired 17,012 shares (Open Market Sale) ($62.3K) |
Loading...